Evidence map›Paper›PMID 40621859›Full record

ReviewAdvanced biology2025

Microphysiological Glomerular Filtration Barriers: Current Insights, Innovations, and Future Applications.

Manon Miran, Kieu Ngo, David Buob, Hanna Debiec, Pierre Ronco, Guillaume Perry

Abstract readReview
In one paragraph

Review in Advanced biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Nanoparticles in the Treatment of Renal Fibrosis.International journal of nanomedicine · 2026
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Manon MiranSorbonne Université, Inserm, Common and Rare Kidney Diseases: from Molecular Events to Precision Medicine, CoRaKiD, Paris, F-75020, France.
Kieu NgoSorbonne Université, CNRS, Laboratoire de Réactivité de Surface, LRS, Paris, F-75005, France.
David BuobSorbonne Université, Inserm, Common and Rare Kidney Diseases: from Molecular Events to Precision Medicine, CoRaKiD, Paris, F-75020, France.
Hanna DebiecSorbonne Université, Inserm, Common and Rare Kidney Diseases: from Molecular Events to Precision Medicine, CoRaKiD, Paris, F-75020, France.
Pierre RoncoSorbonne Université, Inserm, Common and Rare Kidney Diseases: from Molecular Events to Precision Medicine, CoRaKiD, Paris, F-75020, France.
Guillaume PerrySorbonne Université, Inserm, Common and Rare Kidney Diseases: from Molecular Events to Precision Medicine, CoRaKiD, Paris, F-75020, France.ORCID 0000-0001-7754-0281

Funding

Agence Nationale de la Recherche ANR-20-CE18-0027Sorbonne Université
6 · The paper itself

Abstract

Chronic kidney disease (CKD) affects over 850 million individuals worldwide, often progressing to stages requiring dialysis or kidney transplants. Central to kidney function is the glomerular filtration barrier (GFB), which selectively filters waste while retaining essential proteins. Traditional models, including animal studies and 2D cell cultures, fail to fully replicate the GFB's complexity, limiting CKD research. Recent developments in microphysiological systems (MPS), particularly microphysiological glomerular filtration barriers (MPGFB), provide more accurate in vitro models for studying kidney diseases and evaluating therapies. MPGFB systems use organ-on-chip technology to integrate podocytes and glomerular endothelial cells within confined microfluidic environments, closely mimicking GFB's dynamic in vivo conditions. This setup enables detailed permeability analysis, aiding in research on disease mechanisms and drug toxicity. Furthermore, using human-induced pluripotent stem cells in MPGFB platforms allows patient-specific studies, enhancing insights into genetic kidney disorders. This review first examines the GFB's structure and function, focusing on its cellular and extracellular matrix components. It then discusses biological and engineering approaches to MPGFB fabrication, covering materials, 3D design, and flow control. The review concludes with MPGFB applications in disease modeling and drug testing, and addresses improvements needed for refining MPGFB as a key tool in kidney disease research and treatment.

Indexed as

Glomerular Filtration BarrierRenal Insufficiency, ChronicAnimalsHumansLab-On-A-Chip DevicesPodocytesglomerular filtration barriermicrofluidicsmicrophysiological systemsnephrologyorgans‐on‐a‐chip

Identifiers

PMID40621859
PMCPMC12447127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.